Drug analysis: Sprycel

  • ID: 4462154
  • Drug Pipelines
  • 23 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka) is an oral targeted therapy that inhibits several tyrosine kinases including BCR-ABL, c-KIT, and the Src family kinases. The BCR-ABL fusion gene activates a number of signaling pathways that facilitate cancer cell transformation and proliferation, the inhibition of apoptosis, and adhesion and cytoskeleton abnormalities, all of which are characteristics of the disease. The presence of this gene is a result of the Philadelphia chromosome translocation, which is found in over 90% of chronic myeloid leukemia (CML) cases.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Sprycel: Chronic myeloid leukemia (CML)
Sprycel: Acute lymphoblastic leukemia (ALL)

List of Figures
Figure 1: Sprycel for CML - SWOT analysis
Figure 2: Drug assessment summary of Sprycel for CML
Figure 3: Drug assessment summary of Sprycel for CML
Figure 4: Sprycel - SWOT analysis in acute lymphoblastic leukemia
Figure 5: Drug assessment summary for Sprycel in acute lymphoblastic leukemia
Figure 6: Drug assessment summary for Sprycel in acute lymphoblastic leukemia

List of Tables
Table 1: Sprycel drug profile
Table 2: Sprycel pivotal trial data in CML
Table 3: Sprycel ongoing late-phase trial in CML
Table 4: Sprycel and Tasigna trial data in first-line CML
Table 5: Sprycel drug profile
Table 6: Overview of pivotal trial data for Sprycel in acute lymphoblastic leukemia
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll